SKP Share Price

Open 444.00 Change Price %
High 444.00 1 Day 0.00 0.00
Low 444.00 1 Week 0.00 0.00
Close 444.00 1 Month 0.00 0.00
Volume 8648 1 Year 0.00 0.00
52 Week High 2441.00
52 Week Low 1664.00
SKP Important Levels
Resistance 2 444.00
Resistance 1 444.00
Pivot 444.00
Support 1 444.00
Support 2 444.00
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 66.00 1.07%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
More..
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
BAC 22.54 61.00%
BAC 22.54 61.00%
BAC 22.54 61.00%
More..
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
MATD 6.88 -32.88%
More..

Skyepharma PLC (LON: SKP)

SKP Technical Analysis 2
As on 13th Jun 2016 SKP Share Price closed @ 444.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 367.75 & Sell for SHORT-TERM with Stoploss of 460.84 we also expect STOCK to react on Following IMPORTANT LEVELS.
SKP Target for September
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SKP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.skyepharma.com
SKP Address
SKP
46-48 Grosvenor Gardens
London, SW1W 0EB
United Kingdom
Phone: 44 20 7881 0524
Fax: 44 20 7881 1199
SKP Latest News
Interactive Technical Analysis Chart Skyepharma PLC ( SKP LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Skyepharma PLC
SKP Business Profile
Skyepharma PLC, a drug delivery company, develops, manufactures, and sells oral and inhalation pharmaceutical products. Its marketed products include flutiform and ZYFLO CR for treating asthma; Relvar Ellipta/Breo Ellipta for asthma and COPD; Anoro Ellipta for COPD; Paxil CR for depression treatment; Requip Once-a-day and Madopar DR to treat Parkinson’s disease; Triglide for treating lipid disorders; Sular to treat hypertension; Diclofenac-ratiopharm-uno for pain/inflammation; and Lodotra/Rayos to treat rheumatoid arthritis. The company’s marketed products also comprise Coruno to treat angina; Xatral OD/Uroxatral for treating BPH (urinary symptoms); Solaraze for actinic keratosis treatment; and EXPAREL, which is used for pain management. Its development pipeline includes SKP-1041, which has completed Phase II clinical trails for sleep maintenance; and SKP-1052, which has completed Phase I clinical trails for use in reducing the risk of nocturnal hypoglycaemia in insulintreated patients. The company markets its products through specialty pharmaceutical companies worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.